Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients
Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Positive)
Tags
Key Terms
familial adenomatous polyposismedical
An inherited condition caused by a gene mutation that leads to the early development of hundreds to thousands of growths (polyps) in the colon and rectum, which, if untreated, almost always progress to colorectal cancer. Investors care because it creates a clear medical need for genetic testing, ongoing monitoring, preventive surgeries and targeted therapies; like a high-risk household where early alarms and durable fixes have outsized value in diagnostics and treatment markets.
rapamycinmedical
Rapamycin is a prescription drug that slows a key cellular growth and immune response pathway, often described like turning down the speed of a factory assembly line inside cells. Clinically it is used to prevent organ transplant rejection and is researched for cancer and aging-related treatments; for investors, its importance lies in regulatory approvals, patent status, safety profile, and potential to create new markets or extend existing drug franchises.
sirolimusmedical
Sirolimus is a medication that suppresses the immune system and slows abnormal cell growth, acting like a brake to prevent the body from rejecting transplanted organs and to reduce excessive tissue buildup. Investors care because approvals, clinical trial results, patent protection and safety data determine how widely the drug and products that deliver it (like coated stents or creams) can be sold, which directly affects potential revenue and risk.
mtormedical
mTOR is a key protein in cells that acts like a central control switch, coordinating growth, fuel use and repair in response to nutrients and hormones. Investors watch mTOR because drugs that block or tweak its activity are used to treat cancers, metabolic and immune diseases; progress or setbacks in related clinical trials can strongly affect a company’s drug prospects and stock value.
real world datatechnical
Real world data are health and healthcare information collected outside controlled clinical trials — for example, electronic medical records, insurance claims, patient registries, wearable device readings, and patient surveys. Investors use these data to see how a treatment, device, or service actually performs in everyday settings, which helps judge real market demand, safety, cost impact, and likely adoption; think of it as how a car behaves on real roads versus a polished test track.
investigational therapymedical
An investigational therapy is a drug, biological product, or medical treatment that is being tested in clinical trials but has not yet received regulatory approval for general use. Investors track these programs because trial results determine whether the therapy can reach patients and produce revenue; think of it as a prototype being validated — successful trials can boost a company’s value, while failures can sharply lower it.
CHARLOTTE, N.C. & CARDIFF, United Kingdom--(BUSINESS WIRE)--
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program.
FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care.
eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment.
Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa in countries where it is not currently available, allowing clinicians treating FAP patients to prescribe this investigational therapy outside of a clinical trial for the first time.
The program will be available to clinicians globally and is designed to expand access while supporting real-world use. As part of this initiative, Biodexa will also generate Real World Data (RWD) to further advance understanding of FAP and patient experience.
Access through the program is based on patient eligibility, local regulations, and availability of government or private funding.
About Tanner Pharma Group
Tanner Pharma is a specialist pharmaceutical services provider based in Charlotte, NC, USA with offices in Ireland, Switzerland and the UK. The company focuses on improving global access to medicines and, through its Managed Access Programs division, supports manufacturers by providing controlled and compliant access to innovative therapies in countries where they are not commercially available. For more information, visit www.tannerpharma.com.
About Biodexa Pharmaceuticals PLC
Biodexa is a clinical stage biotechnology company developing treatments for diseases with high unmet need. Its lead programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 for Gastrointestinal Stromal Tumors (GIST), and tolimidone for type 1 diabetes. Biodexa is headquartered in Cardiff, UK. For more information, visit www.biodexapharma.com.
